Our Company was incorporated in Singapore in 2008, when we acquired intellectual property rights of a formulation for a fentanyl citrate nasal spray for patient-controlled analgesia.
Our Company's founder, Chairman and CEO, Mr Eddy Lee, then recruited a team of scientists with more than 100 years of expertise in drug development between them, to undertake research in the development of an innovative drug delivery system. This would enable the drugs to be delivered safely, with improved efficacy, ease of use and rate of absorption over existing drug delivery platforms and routes of administration.
Our CEO is a very experienced and highly regarded professional start-up specialist with an impressive track record (e.g., founding GM/CEO of start-ups including Burswood Resort Hotel, Star Cruises PLC and Amcom Telecommunications Ltd).
On November 2008, our research resulted in the development of a drug delivery platform known as WaferiXTM , a wafer-based fast dissolving drug delivery platform, which delivers active pharmaceutical compounds sublingually by placing the wafer under the tongue.
iX Australia was established in Perth, Western Australia as a wholly-owned subsidiary of our Company to be the research and development arm of our Group primarily to conduct human clinical trials.
By November 2009, we commenced our first clinical study (Phase 1 clinical study to investigate the pharmacokinetics profile and bioavailability of WafernylTM ).
Since 2010, we identified, formulated and developed two other products WafermineTM and PheoniXTM , and conducted successful clinical studies for our products. See our products in development here.
We have been granted patents for our WaferiXTM drug delivery platform in Singapore in October 2011, Australia in February 2013, Malaysia in February 2014, New Zealand in September 2014, Japan in July 2015 and Indonesia in October 2015. Patents are pending in other major markets, including the US, Canada, Europe, South Korea and PRC.
In May 2014, iX completed the acquisition of Syrinx Pharmaceuticals Pty Ltd and Chemical Analysis Pty Ltd in Australia. We now have our own manufacturing and laboratory testing facilities that are TGA-approved and cGMP-compliant.
In August 2016, iX announced that we have completed the pre-clinical development of BnoXTM, a sublingual buprenorphine and WafeRestTM, a sublingual melatonin.
In September 2016, iX announced that we have completed a pivotal study confirming bioequivalence and good oral tolerability of PheoniXTM, a sublingual sildenafil wafer. The Group will proceed to apply for registration of PheoniXTM with the Therapeutic Goods Administration in Australia.